Intracellular mutation accumulation caused by POLE mutations or MSI, leads to a high tumor mutational burden (TMB), increased expression of new antigens, and abundant tumor-infiltrating lymphocytes, which result in sensitivity to immune checkpoint inhibitors (Arora et al., 2018). The gene discussed is POLE; the disease is neoplasm.